

Goldstein
EXHIBIT NO. 17
MR 6/4/08

Goldstein, Jeffrey M

From: Goldstein, Jeffrey M
Sent: Thursday, July 18, 2002 3:41 PM
To: Johnston, Alwyn E
Subject: sample requests

Hi Alwyn,

I am a little behind on my responses to the Seroquel sample requests. Hopefully I will now catch up:

1. REDACTED Saitama Medical School. Wants 1 g of quetiapine to look at 5HT1A binding. Approved
2. REDAC Auburn University Alabama. Wants 1 g pure quetiapine for controlled release formulation. I defer to Bob Sepalyak.
3. REDACTED Turkey. Wants 3 g of quetiapine to study diabetogenic and hyperlipidemia side effects of quetiapine and other atypicals. This would be an interesting study but carries substantial risks that we do not differentiate from olanzapine or clozapine. This would be damaging. On the other hand, positive data would be very advantageous and allow us to further distance ourselves from the diabetogenic atypicals. This is a hot topic and I would not want to enter into a study that could provide any data that could influence regulatory authorities against us. I think this needs some further discussion at GPT level.
4. REDACTED University of Melbourne, Australia. Wants 20 g of quetiapine to look at antidepressant effect of quetiapine in animal models. Also want financial aid of US \$20,502. This needs to go to the global IIT Team for approval, but scientifically it seems straightforward. I would want to know if he has published on antidepressant effects of any other atypicals in these models. His choice of comparator is fluoxetine and we could be at a disadvantage. I would prefer a second comparator agent to be another atypical where we have a fighting chance to show an effect (risperidone or olanzapine). Provisionally approved with modification.

These were all I had at the moment.

Thanks,

Jeff